Abstract
Minocycline, an antibiotic of the tetracycline family, has been shown to display neurorestorative or neuroprotective properties in various models of neurodegenerative diseases. In particular, it has been shown to delay motor alterations, inflammation and apoptosis in models of Huntingtons disease, amyotrophic lateral sclerosis and Parkinsons disease. Despite controversies about its efficacy, the relative safety and tolerability of minocycline have led to various clinical trials. Recently, we reported the antipsychotic effects of minocycline in patients with schizophrenia. In a pilot investigation, we administered minocycline as an open-label adjunct to antipsychotic medication to patients with schizophrenia. The results of this trial suggested that minocycline might be a safe and effective adjunct to antipsychotic medications, and that augmentation with minocycline may prove to be a viable strategy for “boosting” antipsychotic efficacy and for treating schizophrenia. The present review summarizes the available data supporting the clinical testing of minocycline for patients with schizophrenia. In addition, we extend our discussion to the potential applications of minocycline for combining this treatment with cellular and molecular therapy.
Keywords: Minocycline, schizophrenia, apoptosis, inflammation
CNS & Neurological Disorders - Drug Targets
Title: Clinical Potential of Minocycline for Schizophrenia
Volume: 7 Issue: 4
Author(s): Tsuyoshi Miyaoka
Affiliation:
Keywords: Minocycline, schizophrenia, apoptosis, inflammation
Abstract: Minocycline, an antibiotic of the tetracycline family, has been shown to display neurorestorative or neuroprotective properties in various models of neurodegenerative diseases. In particular, it has been shown to delay motor alterations, inflammation and apoptosis in models of Huntingtons disease, amyotrophic lateral sclerosis and Parkinsons disease. Despite controversies about its efficacy, the relative safety and tolerability of minocycline have led to various clinical trials. Recently, we reported the antipsychotic effects of minocycline in patients with schizophrenia. In a pilot investigation, we administered minocycline as an open-label adjunct to antipsychotic medication to patients with schizophrenia. The results of this trial suggested that minocycline might be a safe and effective adjunct to antipsychotic medications, and that augmentation with minocycline may prove to be a viable strategy for “boosting” antipsychotic efficacy and for treating schizophrenia. The present review summarizes the available data supporting the clinical testing of minocycline for patients with schizophrenia. In addition, we extend our discussion to the potential applications of minocycline for combining this treatment with cellular and molecular therapy.
Export Options
About this article
Cite this article as:
Miyaoka Tsuyoshi, Clinical Potential of Minocycline for Schizophrenia, CNS & Neurological Disorders - Drug Targets 2008; 7 (4) . https://dx.doi.org/10.2174/187152708786441858
DOI https://dx.doi.org/10.2174/187152708786441858 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Microglia and its Genetics in Alzheimer's Disease
Current Alzheimer Research Neurotrophic Factors in the Pathogenesis of Neurological Disorders with Mental Retardation in Children
Current Pediatric Reviews Tetracyclines and Pulmonary Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Temporal Expression of Mutant TDP-43 Correlates with Early Amyotrophic Lateral Sclerosis Phenotype and Motor Weakness
Current Neurovascular Research Nerve Growth Factor: Structure, Function and Therapeutic Implications for Alzheimers Disease
Current Drug Targets - CNS & Neurological Disorders Immunophilins in Nervous System Degeneration and Regeneration
Current Topics in Medicinal Chemistry Insights into the Structure, Function, and Regulation of Human Cytochrome P450 1A2
Current Drug Metabolism CEST MRI for Molecular Imaging of Brain Metabolites
Current Molecular Imaging (Discontinued) Healthy Gut, Healthy Brain: The Gut Microbiome in Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Dual Effects of Antioxidants in Neurodegeneration: Direct Neuroprotection against Oxidative Stress and Indirect Protection via Suppression of Gliamediated Inflammation
Current Pharmaceutical Design Phytochemicals in the Treatment of Alzheimer’s Disease: A Systematic Review
Current Drug Targets Flavones from Root of Scutellaria Baicalensis Georgi: Drugs of the Future in Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Targeting Neurotrophic/Growth Factor Expression and Signaling for Antidepressant Drug Development
CNS & Neurological Disorders - Drug Targets Reorganizing Metals: the Use of Chelating Compounds as Potential Therapies for Metal-Related Neurodegenerative Disease
Current Topics in Medicinal Chemistry Proteins of the Esterase Family: Patents for Some Proteins in Search of Metabolic Functions
Recent Patents on Biomarkers Alzheimer's Disease: Related Targets, Synthesis of Available Drugs, Bioactive Compounds Under Development and Promising Results Obtained from Multi-target Approaches
Current Drug Targets Lipid Raft Alterations in Aged-Associated Neuropathologies
Current Alzheimer Research Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry State Dissociation, Human Behavior, and Consciousness
Current Topics in Medicinal Chemistry Age-Related Changes in Motor Cortical Properties and Voluntary Activation of Skeletal Muscle
Current Aging Science